Capmatinib (dihydrochloride)
Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM) . Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase[1][2][3].
Product Specifications
CAS Number
1197376-85-4
Product Name Alternative
INC280 (dihydrochloride) ; INCB28060 (dihydrochloride)
UNSPSC
12352005
Hazard Statement
H371
Target
Apoptosis; c-Met/HGFR
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/capmatinib-dihydrochloride.html
Purity
99.82
Solubility
DMSO : 5.83 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(NC)C1=CC=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1F.Cl.Cl
Molecular Formula
C23H19Cl2FN6O
Molecular Weight
485.34
Precautions
H371
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human GPR32-Strep full length protein-synthetic nanodisc
Human GPR32-Strep full length protein-synthetic nanodisc